Table 2 Remission after treatment with plasma exchange for recurrent post-transplant FSGS: a descriptive comparison using all available data
Remission | ||
|---|---|---|
Yesa | No | |
Pre-treatment characteristics | ||
Age at time of treatment (years), median (IQR) | 17 (13,32) | 17 (11,38) |
< 18 years, n (%) | 89 (50.6 %) | 30 (50.8 %) |
Male, n (%) | 106 (65.8 %) | 20 (39.2 %) |
Pre-treatment proteinuria (g/day), median (IQR) | 7 (5,12) | 9 (6,15) |
Biopsy conducted at time of recurrence, n (%) | 157 (77.3 %) | 54 (85.7 %) |
Time to recurrence (days), median (IQR) | 3 (1,14) | 7 (1,60) |
Kidney transplant type, n (%) | ||
Living donor transplant | 47 (35.1 %) | 15 (36.6 %) |
Deceased donor transplant | 87 (64.9 %) | 26 (63.4 %) |
Treatment characteristics | ||
Time from recurrence to start of plasma exchange (days), median (IQR) | 1 (0,2) | 1 (0,7) |
Delayed treatment start, n (%) | ||
More than two weeks | 15 (9.0 %) | 13 (20.6 %) |
More than one month | 10 (6.0 %) | 12 (19.1 %) |
Total number of plasma exchange sessions, median (IQR) | 12 (10,20) | 12 (9,20) |
Received rituximab | 27 (8.9 %) | 14 (14.0 %) |
Received steroids | 250 (99.2 %) | 86 (98.9 %) |
Post-treatment outcomes | ||
eGFR at follow up (ml/min/1.73 m2), median (IQR) | 60 (37,84) | 15 (15,40) |
Proteinuria at follow-up (g/day), median (IQR) | 0.1 (0,0.5) | 4 (1,6) |
End-stage renal disease (ESRD), n (%) | 31 (10.7 %) | 52 (57.1 %) |
Time to ESRD after transplant (years), median (IQR) | 1.4 (0.3,2.0) | 0.8 (0.3,2.0) |